One-Liner
A web app that auto-generates a modeled revenue-erosion curve for a branded drug post-loss-of-exclusivity, calibrated on historical adalimumab, infliximab, and vedolizumab biosimilar erosion data, for pharma corporate-development teams.
AI Thinking Process
Impossibility Negation Run 2: 'You can't automate the drafting of an oncology drug's biosimilar-erosion timeline — that's an equity-analyst judgement call.' PB016 vedolizumab biosimilar dual-track FDA+EMA signal is newest data point. Historical erosion curves for adalimumab, infliximab, trastuzumab are public.
Thread 3: web app taking (a) drug name, (b) LOE date, (c) filed biosimilar candidates with FDA status. Returns modeled erosion curve calibrated on historical precedents with country-specific rebate curves.
IQVIA + L.E.K. + Simon-Kucher build these bespoke. Bioinformatics Inc Biosimilars Tracker: status only, not modeled erosion. Cortellis/Evaluate Pharma: data-terminal institutional. Memory suspicion: Cortellis may have erosion-modeling module. Flagged for Pass-2 live web search.
G207 TAM ceiling: pharma corp-dev teams ~200-300 globally with active biosimilar interest. At $30-60K ACV, TAM ~$18M. Below venture-scale. Fires G207.
Attempted hedge-fund pivot: reposition as biosimilar/generic erosion alerter for oncology-focused hedge funds, $10-20K/yr. Adds ~500-1000 buyers globally.
Hedge-fund pivot conflicts with T1's retail-biotech-alerts product. Feature-gravity risk: T1 targets retail investors with OS-curve alerts; T3 pivot targets fund PMs with biosimilar erosion modeling. Products would be pulled toward merging, losing both.
KILLED. (a) TAM ceiling sub-venture for pharma corp-dev original scope. (b) Hedge-fund pivot conflicts with T1 and enters Cortellis+Signals Playbook territory. (c) Cortellis+IQVIA are entrenched institutional incumbents.
Kill Reason
Market ceiling is structurally sub-venture. Pharma corporate-development teams with active biosimilar-erosion interest globally number 200-300 accounts. At $30-60K per account annually, the addressable market ceiling is approximately $18M — a profitable lifestyle business, not a venture-scale SaaS. The hedge-fund expansion pivot to capture oncology-focused fund portfolio managers conflicts with the retail biotech OS alerter in this same session, creating feature-gravity risk. Cortellis and IQVIA are entrenched institutional incumbents in the underlying data-terminal space.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.